scholarly journals In Vitro Antimicrobial Susceptibility of Mycobacterium abscessus in Korea

2008 ◽  
Vol 23 (1) ◽  
pp. 49 ◽  
Author(s):  
Sunghoon Park ◽  
Shinok Kim ◽  
Eun Mi Park ◽  
Hojoong Kim ◽  
O Jung Kwon ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Mycobacterium Abscessus

scholarly journals Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity

2022 ◽  
Vol 12 ◽  
Author(s):  
Siyuan He ◽  
Qi Guo ◽  
Lan Zhao ◽  
Liyun Xu ◽  
Junsheng Fan ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Mycobacterium Abscessus ◽  
Therapeutic Options ◽  
Intracellular Growth ◽  
Bacteriostatic Effect ◽  
Checkerboard Assay ◽  
Reference Strains ◽  
New Strategies

Therapeutic options for treating Mycobacterium abscessus infections are extremely limited; quinolones are important. The in vitro anti-M. abscessus activities of nine quinolones, emphasizing sitafloxacin, were investigated. Antimicrobial susceptibility testing was performed on 10 non-tuberculous mycobacterium reference strains and 194 clinical, M. abscessus isolates. The activity of sitafloxacin against intracellular M. abscessus residing within macrophages was also evaluated. A checkerboard assay was conducted to determine synergy between sitafloxacin and 10 clinically important antibiotics. Among the nine quinolones tested, sitafloxacin exhibited the greatest anti-M. abscessus activity with MIC50 and MIC90 of 1 and 2 mg/L, respectively. Sitafloxacin exerted a bacteriostatic effect on M. abscessus and inhibited the intracellular growth of M. abscessus at concentrations equivalent to clarithromycin. No antagonism between sitafloxacin and 10 clinically important anti-M. abscessus antibiotics was evident. In summary, sitafloxacin exhibited a significant advantage relative to other quinolones in inhibiting the growth of M. abscessus in vitro, suggesting the potential inclusion of sitafloxacin in new strategies to treat M. abscessus infections.

scholarly journals Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease

2021 ◽  
Author(s):  
Youngmok Park ◽  
Yea Eun Park ◽  
Byung Woo Jhun ◽  
Jimyung Park ◽  
Nakwon Kwak ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Pulmonary Disease ◽  
Drug Susceptibility ◽  
Mycobacterium Abscessus ◽  
Beta Lactams ◽  
In Vitro Susceptibility ◽  
Referral Hospitals ◽  
Microbiological Cure ◽  
Culture Conversion

Abstract Objectives Current guidelines recommend a susceptibility-based regimen for Mycobacterium abscessus subspecies abscessus pulmonary disease (MAB-PD), but the evidence is weak. We aimed to investigate the association between treatment outcomes and in vitro drug susceptibility to injectable antibiotics in MAB-PD patients. Methods We enrolled MAB-PD patients treated with intravenous amikacin and beta-lactams for ≥4 weeks at four referral hospitals in Seoul, South Korea. Culture conversion and microbiological cure at one year were evaluated based on susceptibility to injectable antibiotics among patients treated with those antibiotics for ≥ 2 weeks. Results A total of 82 patients were analysed. The mean age was 58.7 years, and 65.9% were women. Sputum culture conversion and microbiological cure were achieved in 52.4% and 41.5% of patients, respectively. Amikacin was the most common agent to which the M. abscessus subspecies abscessus isolates were susceptible (81.7%); 9.8% and 24.0% of the isolates were resistant to cefoxitin and imipenem, respectively. The clarithromycin-inducible resistance (IR) group (n = 65) had a lower microbiological cure rate than the clarithromycin-susceptible group (35.4% vs. 64.7%). The treatment outcomes appeared to be similar regardless of in vitro susceptibility results with regard to intravenous amikacin, cefoxitin, imipenem, and moxifloxacin. In the subgroup analysis of the clarithromycin-IR group, the treatment outcomes did not differ according to antibiotic susceptibility. Conclusions We did not find evidence supporting the use of susceptibility-based treatment with intravenous amikacin and beta-lactams in patients with MAB-PD. Further research would be required.

scholarly journals Association of Antimicrobial Susceptibility and Treatment Outcome in Acne Vulgaris Patients: A Pilot Study

2020 ◽  
Vol 12 (04) ◽  
pp. 233-238
Author(s):  
Ashvini K. Yadav ◽  
Suneel Bhooshan ◽  
Allen Johnson ◽  
Dinesh P. Asati ◽  
Shashwati Nema ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Antimicrobial Susceptibility ◽  
Acne Vulgaris ◽  
Tertiary Care ◽  
Care Hospital ◽  
In Vitro Susceptibility ◽  
Persistent Infections ◽  
Significant Difference ◽  
Cutibacterium Acnes

Abstract Purpose Cutibacterium acnes (C. acnes) is an emerging pathogen that is highly resistant to antibiotics and is capable of causing persistent infections that are difficult to treat. Methods & Materials Acne vulgaris patients visiting dermatology OPD of our tertiary care hospital during the study period of 2 months were recruited. Skin swabs were collected, and the sample was processed on 5% sheep-blood agar for anaerobic culture by the GasPak method. Isolates were identified by the standard biochemical test. Antimicrobial susceptibility testing was performed for clinically relevant antibiotics by the E-strip method. The clinical response was evaluated after 1-month follow-up to the prescribed antibiotics. Results Minocycline, doxycycline, ceftriaxone, and tetracycline were the most effective antibiotics. Nonsusceptibility to clindamycin and erythromycin were observed in 11.9% and 31% isolates, respectively, with 9.5% isolates being nonsusceptible to both. For none of the antibiotics we found significant difference in the proportion of susceptible and nonsusceptible isolates between mild, moderate, and severe grades of acne vulgaris. For none of the antibiotic regimens, significant difference was observed between nonresponders and responders. Twenty-seven patients received clindamycin and among them 16 of 19 responders and 6 of 8 nonresponders yielded growth of clindamycin-susceptible isolates (p = 0.57). Conclusion We observed significant prevalence of resistant strains of C. acnes among patients with acne vulgaris. No association was observed between in vitro susceptibility results and treatment outcome.

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci

1995 ◽  
Vol 21 (1) ◽  
pp. 47-50 ◽  
Author(s):  
Collin Freeman ◽  
Ann Robinson ◽  
Brian Cooper ◽  
Mary Mazens-Sullivan ◽  
Richard Quintiliani ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility

scholarly journals Yersinia enterocolitica: In Vitro Antimicrobial Susceptibility

1978 ◽  
Vol 13 (5) ◽  
pp. 888-890 ◽  
Author(s):  
M. Raevuori ◽  
S. M. Harvey ◽  
M. J. Pickett ◽  
W. J. Martin
Keyword(s):  
Yersinia Enterocolitica ◽  
Antimicrobial Susceptibility

scholarly journals Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates TargetingMycobacterium tuberculosisandMycobacterium abscessus

2018 ◽  
Vol 62 (5) ◽  
Author(s):  
Rashmi Gupta ◽  
Carolina Rodrigues Felix ◽  
Matthew P. Akerman ◽  
Kate J. Akerman ◽  
Cathryn A. Slabber ◽  
...  
Keyword(s):  
Mycobacterium Abscessus ◽  
Cross Resistance ◽  
Human Pathogens ◽  
Intrinsic Resistance ◽  
Content Type ◽  
Starting Point ◽  
Scalable Synthesis ◽  
High Level ◽  
Novel Drug

ABSTRACTMycobacterium tuberculosisand the fast-growing speciesMycobacterium abscessusare two important human pathogens causing persistent pulmonary infections that are difficult to cure and require long treatment times. The emergence of drug-resistantM. tuberculosisstrains and the high level of intrinsic resistance ofM. abscessuscall for novel drug scaffolds that effectively target both pathogens. In this study, we evaluated the activity of bis(pyrrolide-imine) gold(III) macrocycles and chelates, originally designed as DNA intercalators capable of targeting human topoisomerase types I and II (Topo1 and Topo2), againstM. abscessusandM. tuberculosis. We identified a total of 5 noncytotoxic compounds active against both mycobacterial pathogens under replicatingin vitroconditions. We chose one of these hits, compound 14, for detailed analysis due to its potent bactericidal mode of inhibition and scalable synthesis. The clinical relevance of this compound was demonstrated by its ability to inhibit a panel of diverseM. tuberculosisandM. abscessusclinical isolates. Prompted by previous data suggesting that compound 14 may target topoisomerase/gyrase enzymes, we demonstrated that it lacked cross-resistance with fluoroquinolones, which target theM. tuberculosisgyrase.In vitroenzyme assays confirmed the potent activity of compound 14 against bacterial topoisomerase 1A (Topo1) enzymes but not gyrase. Novel scaffolds like compound 14 with potent, selective bactericidal activity againstM. tuberculosisandM. abscessusthat act on validated but underexploited targets like Topo1 represent a promising starting point for the development of novel therapeutics for infections by pathogenic mycobacteria.

scholarly journals Etiology and in vitro antimicrobial susceptibility profile of strains isolated from bovine mastitis in dairy herds from the midwest region of Santa Catarina state, Brazil

2017 ◽  
Vol 11 (4) ◽  
pp. 219-225
Author(s):  
Mylena Karoline Valmorbida ◽  
Danielle Correia dos Santos Carneiro ◽  
Keila Catarina Prior ◽  
Eliete Griebeler ◽  
Marcella Zampoli Troncarelli ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Bovine Mastitis ◽  
Dairy Herds ◽  
Santa Catarina ◽  
Antimicrobial Susceptibility Profile ◽  
Midwest Region ◽  
Santa Catarina State

scholarly journals Gentamicin susceptibility among a sample of multi-drug resistantNeisseria gonorrhoeaeisolates in India

2016 ◽  
pp. AAC.01907-16 ◽  
Author(s):  
Manju Bala ◽  
Vikram Singh ◽  
Aradhana Bhargava ◽  
Monika Kakran ◽  
Naveen Chandra Joshi ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Treatment Outcomes ◽  
Treatment Option ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Dual Therapy ◽  
Clinical Treatment ◽  
Antimicrobial Susceptibility Testing ◽  
Effective Treatment Option

Antimicrobial susceptibility testing of 258N. gonorrhoeaeisolates by Etest determined that 60.1% were MDR while 5% strains had decreased susceptibility to currently recommended extended-spectrum cephalosporins (ESCs). Among these, 84.5% MDR and 76.9% strains having decreased susceptibility to ESCs were susceptible to gentamicin. No MDR isolate was resistant to gentamicin. Thesein vitroresults suggest that gentamicin might be an effective treatment option for the MDR strains and in dual therapy for gonorrhea. However, further research regarding the clinical treatment outcomes is essential.

scholarly journals Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
James D. Blanchard ◽  
Valerie Elias ◽  
David Cipolla ◽  
Igor Gonda ◽  
Luiz E. Bermudez
Keyword(s):  
Effective Treatment ◽  
Mouse Models ◽  
Mycobacterium Avium ◽  
Nontuberculous Mycobacteria ◽  
Mycobacterium Abscessus ◽  
Content Type ◽  
Number Of Individuals ◽  
Intranasal Instillation

ABSTRACT Nontuberculous mycobacteria (NTM) affect an increasing number of individuals worldwide. Infection with these organisms is more common in patients with chronic lung conditions, and treatment is challenging. Quinolones, such as ciprofloxacin, have been used to treat patients, but the results have not been encouraging. In this report, we evaluate novel formulations of liposome-encapsulated ciprofloxacin (liposomal ciprofloxacin) in vitro and in vivo. Its efficacy against Mycobacterium avium and Mycobacterium abscessus was examined in macrophages, in biofilms, and in vivo using intranasal instillation mouse models. Liposomal ciprofloxacin was significantly more active than free ciprofloxacin against both pathogens in macrophages and biofilms. When evaluated in vivo, treatment with the liposomal ciprofloxacin formulations was associated with significant decreases in the bacterial loads in the lungs of animals infected with M. avium and M. abscessus. In summary, topical delivery of liposomal ciprofloxacin in the lung at concentrations greater than those achieved in the serum can be effective in the treatment of NTM, and further evaluation is warranted.

In vitro antimicrobial susceptibility of anaerobic bacteria isolated from caprine footrot

2007 ◽  
Vol 55 (1) ◽  
pp. 11-20 ◽  
Author(s):  
Angela Lacombe-Antoneli ◽  
S. Píriz ◽  
S. Vadillo
Keyword(s):  
Antibiotic Treatment ◽  
Antimicrobial Susceptibility ◽  
Antimicrobial Agents ◽  
Anaerobic Bacteria ◽  
Gram Negative ◽  
Western Spain ◽  
Clinical Cases

The in vitro antimicrobial susceptibility of Gram-negative anaerobic bacilli commonly isolated from footrot in goats was studied. A total of 97 isolates belonging to the genera Dichelobacter, Fusobacterium, Prevotella, Porphyromonas and Bacteroides, obtained from clinical cases of footrot in south-western Spain between March 2000 and May 2001, were tested against 25 antimicrobial agents comprising β-lactams, aminoglycosides, macrolides, chloramphenicol, quinolones, lincosamides, sulphonamides and tetracyclines in order to optimise antibiotic treatment of this disease in goats. β-lactams, tetracyclines and metronidazole displayed the highest in vitro efficacy against the species involved in the pathogenesis of footrot.

Sign in / Sign up

Export Citation Format

Share Document